» Articles » PMID: 35692148

Nanoinformatics and Personalized Medicine: An Advanced Cumulative Approach for Cancer Management

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2022 Jun 13
PMID 35692148
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Even though the battle against one of the deadliest diseases, cancer, has advanced remarkably in the last few decades and the survival rate has improved significantly; the search for an ultimate cure remains a utopia. Nanoinformatics, which is bioinformatics coupled with nanotechnology, endows many novel research opportunities in the preclinical and clinical development of personalized nanosized drug carriers in cancer therapy. Personalized nanomedicines serve as a promising treatment option for cancer owing to their noninvasiveness and their novel approach. Explicitly, the field of personalized medicine is expected to have an enormous impact soon because of its many advantages, namely its versatility to adapt a drug to a cohort of patients.

Objective: The current review explains the application of this newly emerging field called nanoinformatics to the field of precision medicine. This review also recapitulates how nanoinformatics could hasten the development of personalized nanomedicine for cancer, which is undoubtedly the need of the hour.

Conclusion: This approach has been facilitated by a humongous impending field named Nanoinformatics. These breakthroughs and advances have provided insight into the future of personalized medicine. Imperatively, they have been enabling landmark research to merge all advances, creating nanosized particles that contain drugs targeting cell surface receptors and other potent molecules designed to kill cancerous cells. Nanoparticle- based medicine has been developing and has become a center of attention in recent years, focusing primely on proficient delivery systems for various chemotherapy drugs.

Citing Articles

New Theobromine Apoptotic Analogue with Anticancer Potential Targeting the EGFR Protein: Computational and Studies.

Eissa I, Yousef R, Elkaeed E, Alsfouk A, Husein D, Ibrahim I ACS Omega. 2024; 9(14):15861-15881.

PMID: 38617602 PMC: 11007702. DOI: 10.1021/acsomega.3c08148.


Current Intellectual Glance Over Nanoparticles in Cancer and Neurodegenerative Research.

Bhattacharya T, Shen B, Greig N, Kamal M Curr Med Chem. 2023; 30(3):251-254.

PMID: 36883251 PMC: 11334053. DOI: 10.2174/092986733003221121163821.

References
1.
Wu D, Rice C, Wang X . Cancer bioinformatics: a new approach to systems clinical medicine. BMC Bioinformatics. 2012; 13:71. PMC: 3424139. DOI: 10.1186/1471-2105-13-71. View

2.
Maojo V, Martin-Sanchez F, Kulikowski C, Rodriguez-Paton A, Fritts M . Nanoinformatics and DNA-based computing: catalyzing nanomedicine. Pediatr Res. 2010; 67(5):481-9. DOI: 10.1203/PDR.0b013e3181d6245e. View

3.
Kakkar A, Traverso G, Farokhzad O, Weissleder R, Langer R . Evolution of macromolecular complexity in drug delivery systems. Nat Rev Chem. 2019; 1(8). PMC: 6613785. DOI: 10.1038/s41570-017-0063. View

4.
Wang W, Sedykh A, Sun H, Zhao L, Russo D, Zhou H . Predicting Nano-Bio Interactions by Integrating Nanoparticle Libraries and Quantitative Nanostructure Activity Relationship Modeling. ACS Nano. 2017; 11(12):12641-12649. PMC: 5772766. DOI: 10.1021/acsnano.7b07093. View

5.
Shamay Y, Shah J, Isik M, Mizrachi A, Leibold J, Tschaharganeh D . Quantitative self-assembly prediction yields targeted nanomedicines. Nat Mater. 2018; 17(4):361-368. PMC: 5930166. DOI: 10.1038/s41563-017-0007-z. View